Rivastigmine Tartrate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

51 API Suppliers, 19 USDMF, 12 CEP/COS, 12 EU WC, 20 KDMF, 5 NDC API, 26 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

8 Drugs in Development

8 Drugs in Development

INTERMEDIATES

9 Intermediate Suppliers

9 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

279 FDF Dossiers, 46 FDA Orange Book, 199 Europe, 29 Canada, 5 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - EQ 1.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 4.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

4 SPI Pharma, 10 DKSH, 3 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 Kirsch Pharma, 4 ACG Worldwide, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 8 BASF, 10 Corel Pharma Chem, 2 DFE Pharma, 1 Finar, 6 Gangwal Chemicals, 4 Ideal Cures, 2 Ingredion Pharma Solutions, 10 Kerry, 1 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 10 Microlex e.U, 2 Nitika Pharmaceutical Specialities, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 3 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 17 Roquette, 8 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 8 Sigachi Industries, 2 Silverline Chemicals, 2 The Dow Chemical Company, 1 Valens Pharmachem, 2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

44 Coating Systems & Additives, 39 Fillers, Diluents & Binders, 20 Thickeners and Stabilizers, 15 Direct Compression, 15 Controlled & Modified Release, 15 Lubricants & Glidants, 12 Granulation, 10 Film Formers & Plasticizers, 10 Co-Processed Excipients, 9 Empty Capsules, 9 Taste Masking, 8 Disintegrants & Superdisintegrants, 7 Chewable & Orodispersible Aids, 6 Emulsifying Agents, 5 Topical, 5 Coloring Agents, 4 Rheology Modifiers, 4 Vegetarian Capsules, 4 API Stability Enhancers, 3 Solubilizers, 1 Parenteral, 1 Surfactant & Foaming Agents

DIGITAL CONTENT

7 News #PharmaBuzz

7 News #PharmaBuzz

GLOBAL SALES INFORMATION

10 US Medicaid Prescriptions, 12 Regulatory FDF Prices

MARKET PLACE

3 APIs

3 APIs

REF. STANDARDS & IMPURITIES

3 EDQM, 2 Others

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 20823 / DOSAGE - CAPSULE;ORAL - EQ 4.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
RIVASTIGMINE TARTRATE(UNII: 9IY2357JPE) (RIVASTIGMINE - UNII:PKI06M3IW0)	RIVASTIGMINE	6mg \| 4.5mg \| 3mg \| 1.5mg

Inactive Ingredients

Ingredient Name	Avera McKennan Hospital	Novartis Pharmaceuticals Corporation	Sandoz Inc
CELLULOSE, MICROCRYSTALLINE(OP1R32D61U)
FERRIC OXIDE RED(1K09F3G675)
FERRIC OXIDE YELLOW(EX438O2MRT)
GELATIN(2G86QN327L)
HYPROMELLOSES(3NXW29V3WO)
MAGNESIUM STEARATE(70097M6I30)
SILICON DIOXIDE(ETJ7Z6XBU4)
TITANIUM DIOXIDE(15FIX9V2JP)

Setid 4e775022 4b71 4716 Bc9b F374edaf9edb Applno 20823 Form Capsule Oral Dosage Eq 4 5mg Base - Drug Product Composition: Rivastigmine Tartrate